pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

25,092 catalysts · 5,445 approval · 5,000 device 510k · 4,728 grant · 3,128 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 21 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2023-02-08×clear all
type
  • approval5,445
  • device 510k5,000
  • grant4,728
  • 8k filing3,128
  • device pma2,000
  • device recall2,000
recall
1,126
  • device adverse event1,000
  • earnings584
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Oct 16, 2023

    16
    ›Oct 19, 2023approval1028d agoIBANDRONATE SODIUM — FDA approvalIBANDRONATE SODIUM

    Sponsor: DR REDDYS LABS LTD. Form: TABLET. Route: ORAL

    full page →IBANDRONATE SODIUM →fda approvals ↗
    ›Oct 19, 2023approval1028d agoIBANDRONATE SODIUM — FDA approvalIBANDRONATE SODIUM

    Sponsor: DR REDDYS LABS LTD. Form: TABLET. Route: ORAL

    full page →IBANDRONATE SODIUM →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗

    Week of Oct 23, 2023

    10
    ›Oct 23, 2023approval1024d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Oct 23, 2023approval

    Week of Oct 30, 2023

    15
    ›Oct 30, 2023approval1017d agoONDANSETRON — FDA approvalSandoz Inc

    Sponsor: IPCA LABS LTD. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL

    full page →fda approvals ↗
    ›Oct 30, 2023approval

    Week of Nov 6, 2023

    9
    ›Nov 6, 2023approval1010d agoIDARUBICIN HYDROCHLORIDE — FDA approvalIDARUBICIN HYDROCHLORIDE

    Sponsor: PFIZER. Form: SOLUTION. Route: INTRAVENOUS

    full page →IDARUBICIN HYDROCHLORIDE →fda approvals ↗
    ›Nov 7, 2023approval
    ← prev
    page 12 of 502
    next →
    1024d ago
    BUDESONIDE — FDA approvalbudesonide DR

    Sponsor: RISING. Form: CAPSULE, DELAYED RELEASE. Route: ORAL

    full page →budesonide DR →fda approvals ↗
    ›Oct 23, 2023approval1024d agoOSELTAMIVIR PHOSPHATE — FDA approvalOSELTAMIVIR PHOSPHATE

    Sponsor: AJANTA PHARMA LTD. Form: FOR SUSPENSION. Route: ORAL

    full page →OSELTAMIVIR PHOSPHATE →fda approvals ↗
    ›Oct 23, 2023approval1024d agoOSELTAMIVIR PHOSPHATE — FDA approvalOSELTAMIVIR PHOSPHATE

    Sponsor: AJANTA PHARMA LTD. Form: FOR SUSPENSION. Route: ORAL

    full page →OSELTAMIVIR PHOSPHATE →fda approvals ↗
    ›Oct 23, 2023approval1024d agoAMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approvalamoxicillin

    Sponsor: SANDOZ INC. Form: FOR SUSPENSION. Route: ORAL

    full page →amoxicillin →fda approvals ↗
    ›Oct 25, 2023approval1022d agoURSODIOL — FDA approvalURSODIOL

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →URSODIOL →fda approvals ↗
    ›Oct 26, 2023approval1021d agoVABYSMO (FARICIMAB-SVOA) — FDA approvalfaricimab

    Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INTRAVITREAL

    full page →faricimab →fda approvals ↗
    ›Oct 26, 2023approval1021d agoOMVOH (MIRIKIZUMAB-MRKZ) — FDA approvalmirikizumab

    Sponsor: ELI LILLY AND CO. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →mirikizumab →fda approvals ↗
    ›Oct 27, 2023approval1020d agoSCOPOLAMINE — FDA approvalRiconpharma LLC

    Sponsor: PADAGIS US. Form: SYSTEM. Route: TRANSDERMAL

    full page →fda approvals ↗
    ›Oct 27, 2023approval1020d agoIBANDRONATE SODIUM — FDA approvalIBANDRONATE SODIUM

    Sponsor: APOTEX INC. Form: TABLET. Route: ORAL

    full page →IBANDRONATE SODIUM →fda approvals ↗
    1017d ago
    SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval(empagliflozin + metformin hydrochloride ER)

    Sponsor: BOEHRINGER INGELHEIM. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →(empagliflozin + metformin hydrochloride ER) →fda approvals ↗
    ›Oct 30, 2023approval1017d agoGLYXAMBI (EMPAGLIFLOZIN) — FDA approval(empagliflozin + linagliptin)

    Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL

    full page →(empagliflozin + linagliptin) →fda approvals ↗
    ›Oct 30, 2023approval1017d agoSYNJARDY (EMPAGLIFLOZIN) — FDA approvalSYNJARDY

    Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL

    full page →SYNJARDY →fda approvals ↗
    ›Oct 30, 2023approval1017d agoTRIJARDY XR (EMPAGLIFLOZIN) — FDA approval(empagliflozin + linagliptin + metformin hydrochloride) ER

    Sponsor: BOEHRINGER INGELHEIM. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →(empagliflozin + linagliptin + metformin hydrochloride) ER →fda approvals ↗
    ›Oct 31, 2023approval1016d agoCOSENTYX (SECUKINUMAB) — FDA approvalNOVARTIS AG

    Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Oct 31, 2023approval1016d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Oct 31, 2023approval1016d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Oct 31, 2023approval1016d agoIDACIO (ADALIMUMAB-AACF) — FDA approvalIDACIO

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →IDACIO →fda approvals ↗
    ›Oct 31, 2023approval1016d agoWEZLANA (USTEKINUMAB-AUUB) — FDA approvalWEZLANA

    Sponsor: AMGEN INC. Form: INJECTABLE. Route: INTRAVENOUS, SUBCUTANEOUS

    full page →WEZLANA →fda approvals ↗
    ›Oct 31, 2023approval1016d agoWEZLANA (USTEKINUMAB-AUUB) — FDA approvalWEZLANA

    Sponsor: AMGEN INC. Form: INJECTABLE. Route: INTRAVENOUS, SUBCUTANEOUS

    full page →WEZLANA →fda approvals ↗
    ›Nov 1, 2023approval1015d agoVOQUEZNA (VONOPRAZAN FUMARATE) — FDA approvalvonoprazan fumarate

    Sponsor: PHATHOM. Form: TABLET. Route: ORAL

    full page →vonoprazan fumarate →fda approvals ↗
    ›Nov 1, 2023approval1015d agoUZEDY (RISPERIDONE) — FDA approvalDelpor Inc

    Sponsor: TEVA. Form: SUSPENSION, EXTENDED RELEASE. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Nov 3, 2023approval1013d agoHUMIRA (ADALIMUMAB) — FDA approvaladalimumab

    Sponsor: ABBVIE INC. Form: VIAL

    full page →adalimumab →fda approvals ↗
    ›Nov 3, 2023approval1013d agoDOVATO (DOLUTEGRAVIR SODIUM) — FDA approvalViiV Healthcare Company

    Sponsor: VIIV HLTHCARE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    1009d ago
    KEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Nov 7, 2023approval1009d agoTRAMADOL HYDROCHLORIDE — FDA approvalSenores Pharmaceuticals Inc

    Sponsor: SENORES PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 7, 2023approval1009d agoTRAMADOL HYDROCHLORIDE — FDA approvalSenores Pharmaceuticals Inc

    Sponsor: SENORES PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 7, 2023approval1009d agoTRAMADOL HYDROCHLORIDE — FDA approvalSenores Pharmaceuticals Inc

    Sponsor: SENORES PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 7, 2023approval1009d agoTRAMADOL HYDROCHLORIDE — FDA approvalSenores Pharmaceuticals Inc

    Sponsor: SENORES PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 7, 2023approval1009d agoTRAMADOL HYDROCHLORIDE — FDA approvalSenores Pharmaceuticals Inc

    Sponsor: SENORES PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 7, 2023approval1009d agoTRAMADOL HYDROCHLORIDE — FDA approvalSenores Pharmaceuticals Inc

    Sponsor: SENORES PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 8, 2023approval1008d agoZEPBOUND (TIRZEPATIDE) — FDA approvalZEPBOUND

    Sponsor: ELI LILLY AND CO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →ZEPBOUND →fda approvals ↗
    $RDY12.45+2.47%
    $PFE26.62-1.59%
    $RDY12.45+2.47%
    $LLY1215.02-1.37%
    $ABBV250.09+0.85%
    $NVS154.61-1.39%
    $PHAT8.5100-0.70%
    $AMGN414.30-0.70%
    $AMGN414.30-0.70%
    $LLY1215.02-1.37%